Skip to Content

Alk-Abello A/S Class B AKBLF

Morningstar Rating
$22.45 +3.80 (20.38%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AKBLF is trading at a 95% premium.
Price
$17.88
Fair Value
$26.84
Uncertainty
Medium
1-Star Price
$51.91
5-Star Price
$21.13
Economic Moat
Ycpdqw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKBLF is a good fit for your portfolio.

Trading Information

Previous Close Price
$18.65
Day Range
$22.4522.45
52-Week Range
$8.2022.45
Bid/Ask
$18.90 / $39.47
Market Cap
$4.97 Bil
Volume/Avg
20 / 1,800

Key Statistics

Price/Earnings (Normalized)
45.27
Price/Sales
5.37
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
2,752

Comparables

Valuation

Metric
AKBLF
ZEAL
TLX
Price/Earnings (Normalized)
45.27125.11
Price/Book Value
5.8412.8734.54
Price/Sales
5.37100.7310.21
Price/Cash Flow
27.68212.35
Price/Earnings
AKBLF
ZEAL
TLX

Financial Strength

Metric
AKBLF
ZEAL
TLX
Quick Ratio
1.126.231.19
Current Ratio
2.586.251.43
Interest Coverage
124.17−29.301.15
Quick Ratio
AKBLF
ZEAL
TLX

Profitability

Metric
AKBLF
ZEAL
TLX
Return on Assets (Normalized)
8.81%−21.29%3.71%
Return on Equity (Normalized)
13.31%−27.41%11.73%
Return on Invested Capital (Normalized)
11.62%−26.07%18.08%
Return on Assets
AKBLF
ZEAL
TLX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWdjsyglwYzgcx$599.5 Bil
VRTX
Vertex Pharmaceuticals IncPtgcjswnNnsdgbd$117.9 Bil
REGN
Regeneron Pharmaceuticals IncDxclqfzyCzmccwf$108.5 Bil
MRNA
Moderna IncPdlgwjkvXsryz$63.9 Bil
BNTX
BioNTech SE ADRFsgndcdnNgmjg$23.4 Bil
ARGX
argenx SE ADRLwgwfjxtNyx$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncCvznfzscMxnvgd$18.7 Bil
BMRN
Biomarin Pharmaceutical IncXxndcbhzMzkhfd$14.3 Bil
INCY
Incyte CorpYrjcrxgYvqglr$12.9 Bil
UTHR
United Therapeutics CorpVkrhqqxqHqtb$12.1 Bil

Sponsor Center